Berubicin Hydrochloride

Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / August 15, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter ended June 30, 2025 and provided a corporate update. "Every decision we make is grounded in our science and driven by a sense of urgency and responsibility to the patients and families counting on us for better outcomes. We are making excellent progress in our development strategy for TPI 287, working rapidly toward commencing a Phase 2 study for the treatment of GBM in the first half of 2026. Looking ahead, we are continuing to leverage our operational experience and global infrastructure to support TPI 287 while working to get our trial up and running and begin dosing patients with this exciting drug candidate," commented John Climaco, CEO of CNS Pharmaceuticals. TPI 287: Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) and docetaxel, in which it stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. While most taxanes are substrates for multi-drug resistant transporters, which maintain the blood brain barrier (BBB), TPI 287's clinical data suggest it has the potential to cross the BBB and treat CNS tumors. In a Phase 1 trial treating glioblastoma patients with TPI 287 in combination with bevacizumab (Avastin®), the efficacy data included 3 Complete Responses and 9 Partial Responses out of 23 patients evaluable. As previously announced, TPI 287 was granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. CNS Pharmaceuticals plans to engage the FDA on the design of a study potentially focused on the registration of TPI 287 in recurrent GBM in 2025. Summary of Financial Results for the Second Quarter 2025 The net loss for the three months ended June 30, 2025 was approximately $2.4 million compared to approximately $2.5 million for the comparable period in 2024. The change in net loss is largely attributable to declining trial costs on the Berubicin trial. The Company reported research and development expenses of $1.2 million for the three months ended June 30, 2025 compared to approximately $1.1 million for the comparable period in 2024. The increase in research and development expenses during the period were mainly attributed to declining trial costs on the Berubicin trial offset by expenditures preparing for a TPI 287 trial including drug manufacturing. General and administrative expense was approximately $1.2 million for the three months ended June 30, 2025 compared to approximately $1.4 million for the comparable period in 2024. The decrease in general and administrative expense is attributable to decreases of approximately $36,000 in legal and professional expenses, $19,000 in travel expenses, $195,000 in stock-based compensation, which were offset by increases of approximately $51,000 in compensation expense and $29,000 in insurance expense. As of June 30, 2025, the Company had cash of approximately $12.1 million. The Company believes that the cash on hand as of June 30, 2025 is sufficient to fund planned operations into the second half of 2026. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients. For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn. Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, the timing of the start of a trial of TPI 287and the Company's cash runway. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@jtcir.com SOURCE: CNS Pharmaceuticals, Inc.

Houston downtown park and skyline in the morning / iStock, Sean Pavone While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to CNS Pharmaceuticals, RadioMedix and Greater Houston Partnership executives. As an emerging life sciences hub within the Lone Star Bio hotbed , Houston has made a name for itself in multiple ways. It’s known for its work not only in oncology but also in cell and gene therapy and medical devices, noted Verena Kallhoff, senior director of global life sciences at the Greater Houston Partnership. “It’s an incredibly vibrant life sciences ecosystem,” Kallhoff told BioSpace . “Lots of organizations that are playing in it are helping startups become successful, helping medium-sized companies mature. So, lots of activity, but we are a large region, and so that sometimes leads to it not being as well recognized because it’s not quite as concentrated as us being all around one square.” Houston probably needs to be more on the radar screen, said Ebrahim Delpassand, CEO, co-founder and chairman of RadioMedix . The clinical-stage biotech based in Houston develops targeted radiopharmaceuticals for cancer diagnosis, monitoring and therapy. “All of the ingredients that are needed for having a successful biotechnology company exist in Houston,” Delpassand told BioSpace . “We just need to spread the word.” Houston has more than 1,100 established life sciences and biotechnology companies, according to the Greater Houston Partnership. Kallhoff said hundreds of life sciences startups have emerged out of the city’s ecosystem, and many companies from across the globe have come there to advance their technologies. What people might not know about Houston’s life sciences scene, according to Kallhoff, is that it can provide a full pathway for bringing drugs to market. She noted that the city has strong research institutions like The University of Texas MD Anderson Cancer Center, Baylor College of Medicine and Rice University as well as accelerators, incubators and initiatives that help researchers explore how they can move from discovery to commercialization. Proximity to Texas Medical Center and MD Anderson There are multiple advantages to being in Houston, according to Delpassand, Kallhoff and John Climaco, CEO of CNS Pharmaceuticals , a clinical-stage biopharma based in Houston. One of the most significant, according to Delpassand and Kallhoff, is proximity to the world’s largest medical complex, the Texas Medical Center. The center is home to dozens of institutions, including MD Anderson, Baylor and Rice. Climaco cited proximity to MD Anderson as an advantage for companies like CNS, which is developing a pipeline of anti-cancer drug candidates. “If you’re in the oncology world, that’s the gold standard anywhere in the world,” Climaco told BioSpace about MD Anderson, which has the largest cancer clinical trials program. It had 1,556 trials in fiscal year 2024 . Having a relationship with MD Anderson is also an advantage for life sciences companies in Houston, according to Climaco. CNS itself has strong ties to the cancer center. Waldemar Priebe, a professor of medicinal chemistry at MD Anderson, founded CNS in 2017. He developed Berubicin, a next-generation anthracycline that was the biopharma’s first drug, at the cancer center. Having a drug with ties to MD Anderson instantly makes people take companies seriously not just in Houston but around the world, according to Climaco. Venture-Friendly, Risk-Friendly Funding Environment Houston’s life sciences companies are in a good funding environment, according to Delpassand. He noted that such an environment is especially important for startups, using RadioMedix as an example. Delpassand shared that for the first few years of the biotech’s existence, he essentially funded the company himself. Then, in 2010, RadioMedix received $2.8 million from the Texas Emerging Technology Fund. Delpassand said the money helped the biotech at a critical time in multiple areas, including expanding its laboratories and hiring more scientists. Climaco noted that Texas has a good early-stage mindset when it comes to funding companies. “I think a lot of investors in Houston are used to being up and down and up and down, and it doesn’t scare them,” he said. “And that’s really important for biotech, because especially the last five years, it has been a seriously wild ride.” I think a lot of investors in Houston are used to being up and down and up and down, and it doesn’t scare them. And that’s really important for biotech, because especially the last five years, it has been a seriously wild ride. John Climaco, CEO of CNS Pharmaceuticals Houston is venture friendly and risk friendly, Climaco said. “It’s not running from risk,” he said. “It’s running toward risk.” While discussing funding opportunities for Houston’s life sciences companies, Kallhoff highlighted the Cancer Prevention and Research Institute of Texas. The $6 billion 20-year initiative dedicated to cancer research and prevention has awarded more than $3.7 billion in grants to research institutions and organizations in the state. Regarding other financial assistance opportunities, the Houston market received $930 million of National Institutes of Health funding in fiscal year 2023 and $180 million in venture capital funding in 2023, according to an April 2024 Colliers life sciences report . Tens of Thousands of Talented Professionals and Experts For companies seeking life sciences talent, Houston has much to offer given its medical schools and other educational institutions that train the future workforce, according to Delpassand. He noted that this is important because personnel is the most valuable asset for any business. The Houston market ranks No. 14 for life sciences total employment, with 27,500 employees, according to a March 2025 Cushman & Wakefield life sciences report . That report also projected the market’s 10-year life sciences employment growth rate at 76.5%. Climaco agreed with Delpassand about the value of Houston’s educational institutions, noting that they’re chock full of experts who can guide and consult with life sciences companies. For scientific advisers and board members specifically, there are tens of thousands of people in Houston that fit that bill, according to Climaco. “You don’t really find that kind of heavy concentration outside the other big hubs,” he said. Affordability for Companies and Their Employees When it comes to a company’s bottom line, Delpassand noted that Houston’s infrastructure costs, including for commercial real estate, are a valuable advantage for those who want to start a business in the city. The asking rent in Houston for the third quarter of 2024 was $47.53 per square foot on a triple net lease where tenants pay property taxes, building insurance and maintenance costs, according to a Transwestern report . That’s lower than rents for Boston ($57.65), San Diego ($52.85) and San Francisco ($61.96). Kallhoff agreed with Delpassand that the cost of doing business in Houston is beneficial. She noted that there’s cost-effective—and abundant—space across the region, whether that’s for wet labs or just desks. According to the Cushman & Wakefield report, Houston has 680,000 square feet of life sciences space under construction and 1.1 million square feet proposed. Houston’s cost of living is also noteworthy, according to Kallhoff and Delpassand. Delpassand said the fact that it’s not as high as in other big cities makes a difference when RadioMedix hires people. According to Salary.com, the cost of living in Houston is 5.4% lower than the national average, a stark contrast to major life sciences hubs Boston and San Francisco , where it’s 53.1% and 86.5% higher, respectively, than the national average. What Comes Next: Areas of Emphasis and More Growth Looking ahead for Houston’s life sciences scene, Kallhoff said oncology and neurology will be among the areas that are big in the next five years. Regarding neurology specifically, she noted that the Texas Legislature is considering setting up a dementia prevention and research institute similar to the Cancer Prevention and Research Institute of Texas. Robust dementia work is already happening at area research institutions, she said. Climaco expects Houston to grow quickly moving forward, although he noted that the life sciences industry is tough right now. When the market turns around, he predicted, the city will probably explode as a biotech hub. “It’s such a science-friendly place,” Climaco said. “And as I said, so much talent in academia for advisers and experts and developers of technology. It’s got a lot going for it.” Interested in more career insights?  Subscribe to  Career Insider  to receive our quarterly life sciences job market reports, career advice and more.